## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%); PEG 2.19 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($270.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Evercore ISI initiates Insulet stock with Outperform rating, $370 price target**
- Source: Investing.com UK | 20251216T120906 | Bullish | Relevance: 100%
- Evercore ISI has initiated coverage on Insulet Corporation (NASDAQ:PODD) with an Outperform rating and a $370 price target, citing the company's market leadership in the underpenetrated insulin pump market. The firm highlighted Insulet's strong execution, unique tubeless design, and broad pharmacy access as key competitive advantages, predicting over 20% growth and significant EPS expansion through 2028. This positive outlook is supported by recent FDA clearance for Omnipod 5 enhancements and expanding recycling programs.

**2. Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference**
- Source: Business Wire | 20251216T120850 | Somewhat-Bullish | Relevance: 100%
- Insulet Corporation announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 11:15 a.m. (Pacific Time). A live webcast and replay of the presentation will be available on the Insulet Investor Relations website. Insulet is a medical device company specializing in tubeless insulin pump technology with its Omnipod® brand.

**3. Insulet expands pod recycling program to all U.S. customers**
- Source: Investing.com India | 20251215T130250 | Bullish | Relevance: 100%
- Insulet Corporation has expanded its Pod recycling program nationwide to all U.S. customers after successful pilot initiatives. The program allows users of its tubeless insulin pump technology to return used Pods for recycling at no cost, furthering the company's environmental initiatives. Insulet (NASDAQ:PODD) maintains strong financial performance, with analysts issuing upward revisions for upcoming earnings expectations.

**4. Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future**
- Source: Yahoo Finance | 20251215T120850 | Bullish | Relevance: 100%
- Insulet Corporation has expanded its Omnipod® U.S. recycling program to all U.S. customers, aiming to divert millions of Pods from landfills. This expansion follows successful pilots in Massachusetts and California, complementing existing takeback programs in other countries. Customers can request a free recycling kit to return used Pods, which are then decontaminated and sent to recycling specialists, supporting Insulet's commitment to sustainability and circular solutions.

**5. Insulet expands Pod recycling program nationwide across US**
- Source: StreetInsider | 20251215T120446 | Bullish | Relevance: 100%
- Insulet Corporation has expanded its Omnipod Pod recycling program to all U.S. customers, following successful pilot programs in Massachusetts and California. This initiative allows users to request free recycling kits for their used Pods, which are then decontaminated and processed at a specialized facility. The program aims to reduce landfill waste and supports Insulet's sustainability goals.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Canaccord Genui | $432 | $428 | +1% |
| 2025-11-21 | Truist Securiti | $412 | $390 | +6% |
| 2025-11-21 | RBC Capital | $380 | $370 | +3% |
| 2025-11-21 | BTIG | $380 | $370 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Canaccord Genui | main | Buy |
| 2025-11-21 | Truist Securiti | main | Buy |
| 2025-11-21 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.30M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Premium valuation (P/E 47x, PEG 2.2x) vulnerable to multiple compression.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +5%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.19 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 20% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.5B |
| Beta | 1.38 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.19 |
| Forward P/E | 47.2 |
| Current P/E | 59.6 |
| YoY Growth | 26.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.5% to -1.3% (+5.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Below SMA200 (0.97x), long-term trend not supportive. MACD histogram bearish (-2.81), momentum weakening. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.28% (CS: 17) | Neutral |
| RSI_14 | 36.3 | Neutral |
| MACD Histogram | -2.81 | Bearish |
| vs SMA20 | 0.927x | Below |
| vs SMA50 | 0.916x | Below |
| vs SMA200 | 0.968x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $291.51
- **Stop Loss:** $270.31 (7.3% risk)
- **Target:** $312.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $16,324.56
- **Portfolio %:** 16.32%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*